Metraipolis › archive › dc_37c5d41d657d

Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of… — Europe PMC PMID:41315923

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41315923
DOI
10.1186/s10194-[numero omesso]-1
License (as archived)
solo-consultazione
Archived
2026-11-08T04:25:55.529Z
SHA-256 of the archived text
f13d7c0a24fe442a067bff6a3fb672b9551201256a28b172b48b6596ee5967ec
Stable URL of this page
https://metraipolis.com/documento/dc_37c5d41d657d

How to cite

Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of… — Europe PMC PMID:41315923 — Europe PMC (en), https://europepmc.org/article/MED/41315923 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_37c5d41d657d (Metraipolis archive dc_37c5d41d657d, sha256 f13d7c0a24fe442a067bff6a3fb672b9551201256a28b172b48b6596ee5967ec)
BibTeX
@misc{dc37c5d41d657d,
  title = {Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of… — Europe PMC PMID:41315923},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41315923},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_37c5d41d657d; sha256 f13d7c0a24fe442a067bff6a3fb672b9551201256a28b172b48b6596ee5967ec},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41315923. Agents can read the archived copy with the MCP tool read_document.